Financial StabilityThe 30% workforce reduction, along with cost reduction announced at 4Q23 earnings, extend cash runway into 2028, providing greater financial stability.
Strategic CollaborationGSK takes full ownership of COVID-19 and flu mRNA vaccines, providing €400M upfront to CureVac, plus additional potential milestones and royalties, strengthening CureVac's financial position.
Strategic RestructuringCureVac’s strategic restructuring focuses resources on the most advanced wholly-owned pipeline assets, potentially accelerating progress in key areas.